The next 15 drugs up for negotiation with Medicare include several blockbusters

By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make them more accessible.
The first 10 drugs to undergo negotiations were announced in late 2023, and the prices were finally agreed in August 2024, with reductions in list price ranging from 38–79% across the selection.
Now, the next 15 drugs to undergo negotiations have been announced by the CMS. The drug companies making these drugs will enter into negotiations with the CMS throughout 2025, with the agreed prices then coming into effect in 2027.
The drugs cover a variety of conditions, from cancer to type 2 diabetes, and asthma. They accounted for 14% of the total gross covered prescription drug costs under Medicare Part D from November 2023 to October 2024.
HHS Secretary Xavier Becerra commented:
“Last year we proved that negotiating for lower drug prices works. Now we plan to build on that record by negotiating for lower prices for 15 additional important drugs for seniors… the Inflation Reduction Act is lowering prices for people on Medicare. HHS will continue negotiating in the best interest of people with Medicare to have access to innovative, life-saving treatments at lower costs.” HHS Secretary Xavier Becerra.
1. Ozempic, Rybelsus and Wegovy (Novo Nordisk) – A once-weekly injectable medication for type 2 diabetes, also used off-label for weight loss, the first oral GLP-1 receptor agonist for type 2 diabetes, helping to lower blood sugar and a higher-dose version of semaglutide, FDA-approved for chronic weight management, respectively.
2. Trelegy Ellipta (GSK – GlaxoSmithKline) – A once-daily inhaler that combines three medications to treat COPD and asthma.
3. Xtandi (Astellas & Pfizer) – An oral medication for metastatic prostate cancer, working as an androgen receptor inhibitor.
4. Pomalyst (Bristol Myers Squibb) – A treatment for multiple myeloma, used in patients who have received prior therapies.
5. Ibrance (Pfizer) – A targeted therapy for HR-positive, HER2-negative breast cancer, taken orally as a CDK4/6 inhibitor.
6. Ofev (Boehringer Ingelheim) – A medication for idiopathic pulmonary fibrosis (IPF) and certain chronic lung diseases, reducing lung function decline.
7. Linzess (AbbVie & Ironwood Pharmaceuticals) – A medication for chronic constipation and irritable bowel syndrome with constipation (IBS-C).
8. Calquence (AstraZeneca) – A BTK inhibitor used to treat chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL).
9. Austedo; Austedo XR (Teva Pharmaceuticals) – A treatment for tardive dyskinesia and Huntington’s disease-related chorea.
10. Breo Ellipta (GSK – GlaxoSmithKline) – A combination inhaler used for COPD and asthma, containing fluticasone and vilanterol.
11. Tradjenta (Boehringer Ingelheim & Eli Lilly) – An oral DPP-4 inhibitor for type 2 diabetes, helping to lower blood sugar.
12. Xifaxan (Bausch Health) – An antibiotic mainly used to treat traveller’s diarrhoea and irritable bowel syndrome with diarrhoea (IBS-D).
13. Vraylar (AbbVie & Gedeon Richter) – An antipsychotic for schizophrenia, bipolar disorder and major depressive disorder (as an adjunct therapy).
14. Janumet; Janumet XR (Merck & Co.) – A combination of sitagliptin and metformin for type 2 diabetes to improve blood sugar control.
15. Otezla (Amgen) – A PDE4 inhibitor for treating psoriasis, psoriatic arthritis, and oral ulcers in Behçet’s disease.
Again this selection targets some of the most high profile drugs and drug makers in the industry, and will no doubt lead to complex negotiations, but this time at least, the companies know more what to expect.
CEO of Novo Nordisk Lars Jørgensen stated:
"I would say, as expected, because of its success in the market, Wegovy and Ozempic and Rybelsus were included in the next round of IRA negotiations. We have some experience in the first round of negotiations where some of our insulins were included and we feel comfortable in our ability to manage this.”
In the future, the CMS will select up to an additional 15 drugs for the third cycle of negotiation, and up to 20 more drugs for each subsequent cycle, as originally outlined in the Inflation Reduction Act.
Related News
-
News PSCI Welcomes Delpharm, Samsung Biologics, and Suven as First Supplier Partners
The pharmaceutical industry continues to evolve with an increasing focus on responsible sourcing, sustainability, and collaboration across the supply chain. Under a new model to recognise suppliers within the pharmaceutical and healthcare industry that... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News Eisai Alzheimer’s drug authorised in UK but still faces obstacles
In partnership with BioArctic AB, pharmaceutical company Eisai has been granted Marketing Authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) for its Alzheimer’s disease drug product Leqembi. -
News Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available. -
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance